MedTrace Logo

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

NCT01761123 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2014-12-10

No results posted yet for this study

Summary

the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of VXA-A1.1 oral vaccine.

Conditions

Interventions

BIOLOGICAL

VXA-A1.1

Sponsors & Collaborators

  • Vaxart

    lead INDUSTRY

Principal Investigators

  • Walter Doll, PhD · Scintipharma

  • David Liebowitz, MD, PhD · Vaxart, Inc.

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761123 on ClinicalTrials.gov